Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Chairman P Roy Vagelos sold 56,213 shares of the company’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $474.48, for a total transaction of $26,671,944.24. Following the completion of the transaction, the chairman now owns 363,638 shares of the company’s stock, valued at $172,538,958.24. The sale was disclosed in a filing with the SEC, which is available at this link.
P Roy Vagelos also recently made the following trade(s):
- On Thursday, August 17th, P Roy Vagelos sold 1,305 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $470.00, for a total transaction of $613,350.00.
- On Wednesday, August 16th, P Roy Vagelos sold 10,986 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $470.17, for a total transaction of $5,165,287.62.
- On Friday, August 18th, P Roy Vagelos sold 15,191 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $470.15, for a total transaction of $7,142,048.65.
- On Thursday, May 25th, P Roy Vagelos sold 9,295 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $458.14, for a total transaction of $4,258,411.30.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 477.80 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The firm’s 50-day moving average is $487.65 and its 200 day moving average is $435.10. The stock has a market capitalization of $50.66 billion, a price-to-earnings ratio of 47.93 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm’s revenue was up 21.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.82 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.85 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/26/regeneron-pharmaceuticals-inc-regn-chairman-sells-26671944-24-in-stock.html.
Large investors have recently bought and sold shares of the stock. FMR LLC raised its stake in Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the period. BlackRock Inc. raised its stake in Regeneron Pharmaceuticals by 0.7% in the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares during the period. Wellington Management Group LLP raised its stake in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the period. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 2.9% in the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares during the period. Finally, State Street Corp raised its stake in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock worth $1,309,861,000 after buying an additional 139,602 shares during the period. Institutional investors and hedge funds own 67.16% of the company’s stock.
REGN has been the subject of several research reports. Vetr lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $408.86 price target for the company. in a research note on Monday, May 1st. BMO Capital Markets reiterated a “hold” rating and issued a $421.00 price target (up from $412.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, May 5th. Cowen and Company reiterated a “hold” rating and issued a $380.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, May 5th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, May 4th. Finally, Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $375.00 to $484.00 in a research note on Friday, May 5th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $495.59.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
